clopidogrel / Generic mfg. - LARVOL DELTA

A ruptured dissecting aneurysm of the anterior radiculomedullary artery caused by hypoplastic vertebral artery angiography: case report. (PubMed, BMC Neurol) - "The occurrence of a ruptured dissecting aneurysm of the anterior radiculomedullary artery induced by vertebral angiography is exceedingly rare. We hypothesize that the sustained high-pressure and high-volume injection of contrast medium was responsible for the arterial dissection and subsequent rupture. During interventional procedures, neurointerventional radiologists should avoid selective angiography of small, hypoplastic vertebral arteries whenever possible to minimize the risk of such complications."

Journal • Cardiovascular • CNS Disorders • Hematological Disorders • Subarachnoid Hemorrhage • Vascular Neurology

Safety and efficacy of sequential intra-arterial and intravenous administration of tirofiban during the periprocedural period of stenting in perforator-rich intracranial arteries. (PubMed, J Neurointerv Surg) - "Periprocedural intra-arterial with intravenous tirofiban reduced early AST, without increasing the risk of hemorrhage, for stenting of perforator-rich intracranial arteries."

Journal • Atherosclerosis • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Diabetes • Giant Cell Arteritis • Hematological Disorders • Ischemic stroke • Metabolic Disorders • Thrombosis

Protamine Overdose–Associated coagulopathy in the setting of post-PCI RCA dissection and cardiac tamponade: A hematologic management dilemma (ASH 2025) - "She received 9000 units of IV heparin and was mistakenly administered 250 mg of protamine instead of 50 mg...Antiplatelet therapy (aspirin and clopidogrel), initially held due to bleeding concerns, was successfully re-initiated 24 hours post-intervention... This case underscores the importance of hematologic vigilance in the setting of protamine overdose during cardiac intervention. Accurate dosing, point-of-care coagulation assessment, and delayed—but timely—re-initiation of antiplatelet therapy can mitigate both bleeding and thrombotic risks. Hematologists should be familiar with protamine pharmacodynamics and emerging reversal strategies, as interdisciplinary collaboration is essential in navigating such high-stakes, dual-risk scenarios."

Cardiovascular • Coronary Artery Disease • Hematological Disorders • Hypotension • Thrombosis

Navigating triple therapy in a high-risk cardiac patient with a covered stent and embolic stroke: A case report (ASH 2025) - "He was diagnosed with NSTEMI, and was initiated on aspirin, clopidogrel, enoxaparin, and nitroglycerin...Persistent cardiogenic shock necessitated Impella CP support, vasopressors (epinephrine, norepinephrine), and inotropes (dobutamine)...Following readmission, neurological evaluation revealed small subacute infarcts, following which anticoagulation with enoxaparin (later apixaban) was initiated alongside DAPT (aspirin, clopidogrel)...Repeat coronary angiography plays a major role here, allowing physicians to assess stent integrity and to make informed decision about de-escalation or continuation of therapy. Unfortunately, there are no current guidelines specifically addressing management strategies for patients with coronary artery aneurysms and recent embolic stroke, underscoring an urgent need for further research in this area."

Case report • Clinical • Cardiomyopathy • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Congestive Heart Failure • Depression • Heart Failure • Hematological Disorders • Ischemic stroke • Nephrology • Peripheral Arterial Disease • Pulmonary Disease • Renal Disease • Respiratory Diseases • Thrombosis

Management of acute coronary syndrome and surgical revascularization in a patient with severe Hemophilia A on emicizumab (ASH 2025) - "Following an initial diagnosis of non-ST elevation myocardial infarction (MI), he received aspirin and therapeutic enoxaparin with FVIII replacement to mitigate bleeding risk. Shortly afterward, his clinical status deteriorated to an ST elevation MI, necessitating the addition of clopidogrel and use of emergent fibrinolytic therapy with further FVIII replacement to target a trough FVIII activity above 100% in the immediate post-lysis period...This case highlights the complex interplay between HA and ACS, balancing thrombotic and bleeding risks, as well as the nuances of lab monitoring for patients on emicizumab. Early identification of these high-risk patients and transfer to a facility with access to specialized laboratory monitoring and multidisciplinary care are required to optimize patient outcomes."

Clinical • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Hemophilia • Hemophilia A • Human Immunodeficiency Virus • Infectious Disease • Myocardial Infarction • Rare Diseases • Rheumatology • Thrombosis

Sonar-AI discovers first comprehensively described cases of GLP-1 receptor agonist associated thrombocytopenia: Faster, cheaper, and better than the 20th century approach of RADAR/sonar (ASH 2025) - "A search of FAERS captured 54 other users of semaglutide, liraglutide, and tirzepatide with (immune) thrombocytopenia...TriNetX Global Collaborative Database Review showed that among both patients with diabetes and patients with obesity but without diabetes, semaglutide use was associated with a lower risk of thrombocytopenia compared with older diabetes and weight loss medications... The SONAR-AI approach facilitated the first comprehensive description of four cases of GLP-1 receptor agonist-associated thrombocytopenia. This effort was completed in four weeks and cost $500. The four cases have been the first comprehensively described cases submitted to FAERS."

Clinical • Diabetes • Genetic Disorders • Hematological Disorders • Immune Thrombocytopenic Purpura • Metabolic Disorders • Obesity • Thrombocytopenia • Thrombocytopenic Purpura

Moyamoya syndrome in sickle cell disease (ASH 2025) - "Treatment is supportive, and prevention of stroke and other complications is the goal with antiplatelet (aspirin or clopidogrel) medications, treatment of associated conditions, and surgical revascularization as definitive therapy...Conclusion : Prompt diagnosis and neurology referral avoided an unnecessary exchange transfusion and lessened the patient's possible morbidity and unnecessary cost to the healthcare system. This case reinforces the need to consider rare differential diagnoses for presentations that can commonly be seen in conditions such as SCD."

Cardiovascular • CNS Disorders • Developmental Disorders • Genetic Disorders • Hematological Disorders • Immunology • Neurofibromatosis • Sickle Cell Disease • Solid Tumor • Thrombosis • Vascular Neurology

Risk of bleeding in chronic lymphocytic leukemia patients in remission treated with covalent Bruton tyrosine kinase inhibitors and contemporary anticoagulant or antiplatelet drugs: Real-world data analysis (ASH 2025) - "The study population was divided into two main cohorts: 1) Cohort 1: CLLpatients in remission treated with covalent BTKi (ibrutinib/acalabrutinib/zanubrutinib) concurrentlytreated with AC (rivaroxaban/apixaban/edoxaban/dabigatran) or AP agents (acetylsalicylicacid/clopidogrel/prasugrel/ticagrelor/ticlopidin), and 2) Cohort 2: CLL patients in remission treated withcovalent BTKi (ibrutinib/acalabrutinib/zanubrutinib) not concurrently treated with AC or AP agents.Cohort 1 was further subdivided into two groups: those treated only with AC and those treated only withAP. CLL patients in remission treated with covalent BTKis experience a significant risk ofbleeding events. This risk is substantially elevated when covalent BTKis therapy is combined with eitheranticoagulant or antiplatelet agents. Notably, our findings indicate no discernible difference in bleedingrisk between AC or AP agents when used concurrently with covalent BTKis."

Clinical • Real-world • Real-world evidence • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia

Risk of bleeding in 15,495 patients with myeloproliferative neoplasms by treatment type and thrombotic history (ASH 2025) - "Treatment categories were definedas follows: no therapy, anticoagulant monotherapy (e.g., warfarin, direct oral anticoagulants [DOACs]); antiplatelet monotherapy (e.g., aspirin, clopidogrel); cytoreductive monotherapy (e.g., hydroxyurea,interferon); and combination therapy, defined as any combination of at least two of the threeaforementioned therapies. Given that themajority of combination therapy regimens included antiplatelet agents, these results underscore thepotential protective role of antiplatelet therapy in managing bleeding risk. These insights may supportclinical decision-making, and guide personalized treatment strategies and risk assessment in patientsdiagnosed with MPN."

Clinical • Essential Thrombocythemia • Myelofibrosis • Myeloproliferative Neoplasm • Polycythemia Vera • Thrombocytosis • Thrombosis

Risk of venous and arterial thromboembolic events following CAR-T therapy in relapsed or refractory non-Hodgkin lymphoma: A propensity-matched multicenter analysis. (ASH 2025) - "The CAR-T cohort included patients who received anyFDA-approved CAR-T product (axi-cel, tisa-cel, liso-cel)...Propensity score matching (1:1, nearest neighbor, caliper 0.1) was performed to balance baselinecharacteristics, including age, sex, race, hypertension, diabetes, hyperlipidemia, chronic ischemic heartdisease, chronic kidney disease (all stages), atrial fibrillation, prior ischemic heart disease, priorthromboembolic events, and use of aspirin, warfarin, apixaban, clopidogrel, ticagrelor, or rivaroxabanbefore CAR-T cell therapy... In this large propensity score–matched analysis of patients with relapsed or refractory NHL, CAR-Ttherapy was associated with a substantially higher 90-day risk of venous thromboembolism and acutelimb ischemia in the early post–CAR-T period. These findings highlight the need for close clinicalmonitoring and the potential role of preventive strategies, such as the use of prophylacticanticoagulation in patients with a low risk of bleeding."

Clinical • Atrial Fibrillation • B Cell Lymphoma • Chronic Kidney Disease • CNS Disorders • Coronary Artery Disease • Diabetes • Diffuse Large B Cell Lymphoma • Dyslipidemia • Follicular Lymphoma • Heart Failure • Hematological Disorders • Hematological Malignancies • Hypertension • Ischemic stroke • Lymphoma • Myocardial Infarction • Nephrology • Non-Hodgkin’s Lymphoma • Respiratory Diseases • Venous Thromboembolism

Distribution and risk for bleeding in patients with cancer by anticoagulant therapy exposure (ASH 2025) - "These included: alcohol abuse, anemia (hemoglobin<10g/dL), antiplatelet therapy (e.g., aspirin, clopidogrel), cancer type (brain, genitourinary [GU], andunresected gastrointestinal [GI]), chemotherapy, fall risk, liver disease, metastatic disease, renal function(estimated glomerular filtrate rate [eGFR] <30mL/min), and uncontrolled hypertension (HTN)...Withinthe combined cohort (n=22,624), AT was significantly associated with bleeding risk: warfarinsubdistribution hazard ratio (sHR) 1.68 (95% CI 1.31, 2.15), direct oral anticoagulation (DOAC) sHR 1.54(95% CI 1.23, 1.94), and low molecular weight heparin (LMWH) 1.43 (95% CI 1.18, 1.73)... In this study of patients with newly diagnosed cancer, AT increased the risk of bleedingrequiring hospitalization. However, the distribution of bleeding site and predictors associated withbleeding remained similar between patients on versus not receiving AT."

Clinical • Atrial Fibrillation • Brain Cancer • Cerebral Hemorrhage • CNS Disorders • Gastrointestinal Cancer • Hepatology • Hypertension • Nephrology • Oncology • Thrombocytopenia • Venous Thromboembolism

Injectable pentosan polysulfate: A novel cause of heparin-induced thrombocytopenia and stroke (ASH 2025) - "Aspirin and Atorvastatin were initiated, and Clopidogrel was deferred due to continuedthrombocytopenia.Due to the unusual presentation of ischemic stroke and isolated thrombocytopenia in a young femalewithout traditional risk factors, a comprehensive diagnostic evaluation was pursued. PPS was therefore identified as thelikely HIT trigger and the patient was treated with Argatroban and transitioned to Apixaban, with plateletcount recovery to 204x10³/μL.This case illustrates the importance of maintaining a broad differential when encountering unexplainedthrombocytopenia and thrombosis, as HIT may arise from unconventional exposures. Obtaining adetailed medication history, which includes unregulated and non-prescribed medications, is essential toidentifying a diagnosis."

Cardiovascular • Hematological Disorders • Immunology • Interstitial Cystitis • Ischemic stroke • Osteoarthritis • Rheumatology • Thrombocytopenia

Thrombotic thrombocytopaenic purpura. (PubMed, Eur Heart J Case Rep) - "Clopidogrel is widely used in patients undergoing percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) due to its antiplatelet effects...The main takeaway is the critical need for clinicians to recognize and address this rare complication to improve patient outcomes. Documenting such cases is essential to raise awareness among healthcare providers about this potentially life-threatening condition."

Journal • Cardiovascular • CNS Disorders • Hematological Disorders • Ischemic stroke • Myocardial Infarction • Renal Disease

Association of Ticagrelor Metabolic SNPs With Adverse Drug Reactions in Patients With Acute Coronary Syndrome. (PubMed, Clin Cardiol) - "The CYP3A5 rs776746 CC genotype is a significant genetic biomarker for ticagrelor-induced dyspnea. Pre-emptive genotyping could enable personalized antiplatelet therapy, such as alternative P2Y₁₂ inhibitors for high-risk CC carriers, to improve patient safety."

Adverse drug reaction • Journal • Acute Coronary Syndrome • Cardiovascular • Pulmonary Disease • CYP3A4 • CYP3A5

TEAR: Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair (clinicaltrials.gov) - P2/3 | N=192 | Completed | Sponsor: Beijing Tiantan Hospital | Recruiting ➔ Completed | Trial completion date: Jun 2025 ➔ Nov 2025 | Trial primary completion date: Dec 2024 ➔ Oct 2025

Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Vascular Neurology

Sekundärprophylaxe der KHK: Clopidogrel ist ASS überlegen. (PubMed, Praxis (Bern 1994)) - No abstract available

Clinical • Journal

Early Postoperative Mortality Risk Factors and Five- and Ten-Year Mortality Rates After Hip Arthroplasty for Femoral Neck Fracture. (PubMed, J Clin Med) - "At 30 days, mortality was higher in males, those on clopidogrel, in patients with lower mobility (lower Parker Score), higher morbidity (higher Charlson Score), NNIS score of 1, higher ASA, patient who underwent hemiarthroplasty, and patients with medical complications post-op...Mortality rate is affected by many risk factors, both non-modifiable factors and modifiable peri-operative variables. Targeted optimization of modifiable peri-operative factors and multidisciplinary geriatric-orthopedic care may improve outcomes in this frail population."

Journal • Anesthesia • Musculoskeletal Diseases • Orthopedics

A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects (clinicaltrials.gov) - P1 | N=65 | Completed | Sponsor: Lumosa Therapeutics Co., Ltd. | Recruiting ➔ Completed

Trial completion • Cardiovascular • Ischemic stroke

Acetyl-leucine in Post-stroke Ataxia (clinicaltrials.gov) - P3 | N=200 | Recruiting | Sponsor: Kafrelsheikh University

New P3 trial • Ataxia • Cardiovascular • Ischemic stroke • Movement Disorders

Ticagrelor promotes arterial healing and shows superiority to clopidogrel in preventing neoatherosclerosis. (PubMed, Blood Vessel Thromb Hemost) - No abstract available

Head-to-Head • Journal • Cardiovascular

Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS (clinicaltrials.gov) - P=N/A | N=150 | Recruiting | Sponsor: McMaster University | Trial completion date: Dec 2027 ➔ Dec 2029 | Trial primary completion date: Jul 2027 ➔ Jul 2029

Trial completion date • Trial primary completion date • Cardiovascular • Genetic Disorders • Hematological Disorders • Thrombosis

Impact of CYP2C19 point-of-care testing on the clinical outcome in patients receiving personalized clopidogrel therapy: systemic review and meta-analysis. (PubMed, Front Pharmacol) - "Genotype-guided antiplatelet therapy using CYP2C19 POC genotyping prior to PCI in ACS/CAD patients may reduce the risk of recurrent myocardial infarction and composite MACEs compared to standard treatment, highlighting the importance of POC genotyping for facilitating rapid and effective therapeutic decision-making. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251157778, identifier CRD420251157778."

Clinical data • Journal • Retrospective data • Review • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Hematological Disorders • Myocardial Infarction • Thrombosis • CYP2C19

Reduced risk of perioperative blood transfusions in coronary surgery: A nationwide study over 18 years. (PubMed, J Cardiothorac Surg) - "The proportion of CABG patients receiving perioperative transfusions in Iceland is relatively high, but the risk of transfusion has decreased markedly during the past two decades. This is most likely attributed to increased focus on patient blood management, including the implementation of transfusion guidelines and perioperative use of heparin titration, viscoelastic testing and cell salvage."

Journal • Chronic Kidney Disease • Nephrology

Association between clopidogrel use and improved survival in critically ill patients with acute kidney injury: insights from MIMIC-IV database. (PubMed, BMC Nephrol) - No abstract available

Journal • Acute Kidney Injury • Nephrology • Renal Disease

Impact of P2Y12 inhibitor pretreatment on periprocedural (type 4a) myocardial infarction and bleeding in NSTEMI. (PubMed, Rev Esp Cardiol (Engl Ed)) - P=N/A | "In NSTEMI patients undergoing PCI, pretreatment with P2Y12 inhibitors, mainly clopidogrel, did not reduce the incidence of type 4a MI but was associated with an increased risk of in-hospital bleeding."

Journal • Cardiovascular • Coronary Artery Disease • Myocardial Infarction